Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 25
1999 47
2000 43
2001 99
2002 119
2003 132
2004 176
2005 220
2006 301
2007 344
2008 421
2009 427
2010 520
2011 502
2012 557
2013 518
2014 594
2015 549
2016 558
2017 538
2018 562
2019 550
2020 631
2021 632
2022 581
2023 151
Text availability
Article attribute
Article type
Publication date

Search Results

8,664 results
Results by year
Filters applied: . Clear all
Page 1
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Masuda N, et al. N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645. N Engl J Med. 2017. PMID: 28564564 Free article. Clinical Trial.
Overall survival was longer in the capecitabine group than in the control group (89.2% vs. 83.6% of the patients were alive at 5 years; hazard ratio for death, 0.59; 95% CI, 0.39 to 0.90; P=0.01). ...The hand-foot syndrome, the most common adverse reaction to capecitabi …
Overall survival was longer in the capecitabine group than in the control group (89.2% vs. 83.6% of the patients were alive at 5 year …
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY; South China Breast Cancer Group (SCBCG). Wang X, et al. JAMA. 2021 Jan 5;325(1):50-58. doi: 10.1001/jama.2020.23370. JAMA. 2021. PMID: 33300950 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the efficacy and adverse effects of low-dose capecitabine maintenance after standard adjuvant chemotherapy in early-stage triple-negative breast cancer. ...The most common capecitabine-related adverse event was hand-foot syndrome (45.2%), with …
OBJECTIVE: To evaluate the efficacy and adverse effects of low-dose capecitabine maintenance after standard adjuvant chemotherapy in …
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans JTR, Stocken D, Praseedom R, Ma YT, Davidson B, Neoptolemos JP, Iveson T, Raftery J, Zhu S, Cunningham D, Garden OJ, Stubbs C, Valle JW, Bridgewater J; BILCAP study group. Primrose JN, et al. Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25. Lancet Oncol. 2019. PMID: 30922733 Free article. Clinical Trial.
In the prespecified per-protocol analysis (210 patients in the capecitabine group and 220 in the observation group), median overall survival was 53 months (95% CI 40 to not reached) in the capecitabine group and 36 months (30-44) in the observation group (adjusted H …
In the prespecified per-protocol analysis (210 patients in the capecitabine group and 220 in the observation group), median overall s …
The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW, Guchelaar HJ, Boven E. Lam SW, et al. Cancer Treat Rev. 2016 Nov;50:9-22. doi: 10.1016/j.ctrv.2016.08.001. Epub 2016 Aug 10. Cancer Treat Rev. 2016. PMID: 27569869 Review.
Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. ...In this review we present the current knowledge on genetic variants, commonly single-nucleotide polymorphisms (SNPs), tested in cohorts of cancer patients and po …
Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. ...In this review we pre …
Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, Zeng S. Lou Y, et al. Chem Res Toxicol. 2016 Oct 17;29(10):1591-1601. doi: 10.1021/acs.chemrestox.6b00215. Epub 2016 Sep 28. Chem Res Toxicol. 2016. PMID: 27631426 Review.
Capecitabine, an oral prodrug of 5-fluorouracil, inhibits DNA synthesis and has received FDA approval for treatment of metastatic colorectal and breast cancers. ...Although current studies describe the possible mechanisms of HFS induced by capecitabine, much remains …
Capecitabine, an oral prodrug of 5-fluorouracil, inhibits DNA synthesis and has received FDA approval for treatment of metastatic col …
Capecitabine for the treatment of pancreatic cancer.
Siddiqui NS, Godara A, Byrne MM, Saif MW. Siddiqui NS, et al. Expert Opin Pharmacother. 2019 Mar;20(4):399-409. doi: 10.1080/14656566.2018.1560422. Epub 2019 Jan 16. Expert Opin Pharmacother. 2019. PMID: 30649964 Review.
Expert opinion: Capecitabine has the advantage over other therapeutics in so much that it has both convenient oral administration and a favorable toxicity profile. Current data has promised the use of capecitabine in all stages of pancreatic cancer. However, predict …
Expert opinion: Capecitabine has the advantage over other therapeutics in so much that it has both convenient oral administration and …
Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Al-Toubah T, Morse B, Strosberg J. Al-Toubah T, et al. Oncologist. 2020 Jan;25(1):e48-e52. doi: 10.1634/theoncologist.2019-0361. Epub 2019 Aug 27. Oncologist. 2020. PMID: 31455747 Free PMC article.
BACKGROUND: Patients with advanced lung neuroendocrine neoplasms (NENs) have few treatment options. Capecitabine and temozolomide have recently showed significant activity in patients with pancreatic neuroendocrine tumors (NETs), but data in lung NETs are limited. ...RESUL …
BACKGROUND: Patients with advanced lung neuroendocrine neoplasms (NENs) have few treatment options. Capecitabine and temozolomide hav …
Capecitabine induced fingerprint loss: Case report and review of the literature.
Deneken-Hernandez Z, Cherem-Kibrit M, Gutiérrez-Andrade L, Rodríguez-Gutiérrez G, Colmenero-Mercado JO. Deneken-Hernandez Z, et al. J Oncol Pharm Pract. 2022 Mar;28(2):495-499. doi: 10.1177/10781552211045009. Epub 2021 Oct 5. J Oncol Pharm Pract. 2022. PMID: 34609922 Review.
After initial treatment with a combined radiotherapy and chemotherapy palliative treatment, hepatic and lung metastasis progression obliged capecitabine oral intake. In 2018, after two years on the fluoropyrimidine (capecitabine), the patient reported adermatoglyphi …
After initial treatment with a combined radiotherapy and chemotherapy palliative treatment, hepatic and lung metastasis progression obliged …
Performance of capecitabine in novel combination therapies in colorectal cancer.
Pouya FD, Rasmi Y, Camci IY, Tutar Y, Nemati M. Pouya FD, et al. J Chemother. 2021 Oct;33(6):375-389. doi: 10.1080/1120009X.2021.1920247. Epub 2021 May 21. J Chemother. 2021. PMID: 34019782 Review.
One of the standard chemotherapy regimens used for colorectal cancer is capecitabine, which is important in monotherapy and combination therapies. ...However, some drugs, such as proton pump inhibitors, are negatively related to capecitabine; therefore, the purpose …
One of the standard chemotherapy regimens used for colorectal cancer is capecitabine, which is important in monotherapy and combinati …
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano Á, García-Sáenz JA, Torres R, de la Haba J, García-Martínez E, Gómez HL, Llombart A, Bofill JS, Baena-Cañada JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Fernández I, Rodríguez-Lescure Á, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Martín M; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group). Lluch A, et al. J Clin Oncol. 2020 Jan 20;38(3):203-213. doi: 10.1200/JCO.19.00904. Epub 2019 Dec 5. J Clin Oncol. 2020. PMID: 31804894 Free PMC article. Clinical Trial.
The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of standard chemotherapy in patients with early TNBC. ...Tolerance of capecitabine was as expected, with 75.2% of patients completing the planned 8 cycles. ...
The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of standard chemotherapy in patients …
8,664 results